MX2016004678A - Composiciones para el tratamiento del cancer. - Google Patents
Composiciones para el tratamiento del cancer.Info
- Publication number
- MX2016004678A MX2016004678A MX2016004678A MX2016004678A MX2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- treating cancer
- treatment
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895308P | 2013-10-24 | 2013-10-24 | |
| PCT/US2014/061418 WO2015061229A1 (en) | 2013-10-24 | 2014-10-20 | Methods and compositions for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016004678A true MX2016004678A (es) | 2017-03-10 |
Family
ID=52993423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004678A MX2016004678A (es) | 2013-10-24 | 2014-10-20 | Composiciones para el tratamiento del cancer. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9511050B2 (enExample) |
| EP (1) | EP3060207A4 (enExample) |
| JP (1) | JP6389884B2 (enExample) |
| KR (1) | KR20160065986A (enExample) |
| CN (1) | CN105848654B (enExample) |
| AU (1) | AU2014340398A1 (enExample) |
| CA (1) | CA2927148A1 (enExample) |
| IL (1) | IL245281A0 (enExample) |
| MX (1) | MX2016004678A (enExample) |
| RU (1) | RU2016114498A (enExample) |
| WO (1) | WO2015061229A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232310B2 (en) * | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| ES2464461T3 (es) | 2008-09-22 | 2014-06-02 | Array Biopharma, Inc. | Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa |
| MX2011004204A (es) | 2008-10-22 | 2011-08-12 | Array Biopharma Inc | Compuestos pirazolo [1,5-a] pirimidina sustituida como inhibidores de cinasa trk. |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| CN102971322B (zh) | 2010-05-20 | 2016-02-17 | 阵列生物制药公司 | 作为trk激酶抑制剂的大环化合物 |
| AU2013245812B2 (en) | 2012-04-12 | 2017-04-06 | Georgetown University | Methods and compositions for treating Ewing's sarcoma family of tumors |
| KR20160065986A (ko) * | 2013-10-24 | 2016-06-09 | 조지타운 유니버시티 | 암 치료용 방법 및 조성물 |
| AU2015328121B2 (en) | 2014-10-09 | 2019-11-21 | Oncternal Therapeutics, Inc. | Indolinone compounds and uses thereof |
| CA2967951C (en) | 2014-11-16 | 2023-11-07 | Array Biopharma, Inc. | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| WO2017075107A1 (en) | 2015-10-26 | 2017-05-04 | Nanda Nisha | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| EP3436434B1 (en) | 2016-03-31 | 2020-07-08 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| DK3439662T3 (da) | 2016-04-04 | 2024-09-02 | Loxo Oncology Inc | Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
| US10613088B2 (en) * | 2016-06-12 | 2020-04-07 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| US10761081B2 (en) * | 2016-06-12 | 2020-09-01 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| CN114569606B (zh) | 2016-07-29 | 2024-04-19 | 英克特诺治疗公司 | 吲哚啉酮化合物的用途 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| KR102747156B1 (ko) * | 2017-02-28 | 2024-12-26 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 전립선 암의 검출 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110845389A (zh) * | 2019-10-17 | 2020-02-28 | 袁健 | 一种新型i型拓扑异构酶抑制剂 |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3483704D1 (de) | 1983-07-22 | 1991-01-17 | Du Pont | Phenylchinolinsaeure und derivate als antitumormittel. |
| DE69922997T2 (de) | 1998-12-04 | 2005-12-15 | Neurosearch A/S | Verwendung von isatinderivaten als ionenkanalaktivierende mittel |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| AU2005323437B2 (en) | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
| WO2006117414A1 (es) | 2005-04-29 | 2006-11-09 | Proyecto De Biomedicina Cima, S.L. | Modelo animal no humano de sarcoma |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| EP2687206B1 (en) | 2006-12-29 | 2017-12-13 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| MX2009011281A (es) | 2007-04-20 | 2010-03-08 | Univ New York State Res Found | Benzimidazol y composiciones farmaceuticas del mismo. |
| TW201346030A (zh) * | 2012-04-02 | 2013-11-16 | Gradalis Inc | 依汶氏(EWING’S)肉瘤雙功能shRNA設計 |
| AU2013245812B2 (en) | 2012-04-12 | 2017-04-06 | Georgetown University | Methods and compositions for treating Ewing's sarcoma family of tumors |
| KR20160065986A (ko) * | 2013-10-24 | 2016-06-09 | 조지타운 유니버시티 | 암 치료용 방법 및 조성물 |
-
2014
- 2014-10-20 KR KR1020167013692A patent/KR20160065986A/ko not_active Withdrawn
- 2014-10-20 JP JP2016526034A patent/JP6389884B2/ja active Active
- 2014-10-20 RU RU2016114498A patent/RU2016114498A/ru not_active Application Discontinuation
- 2014-10-20 EP EP14855801.8A patent/EP3060207A4/en not_active Withdrawn
- 2014-10-20 WO PCT/US2014/061418 patent/WO2015061229A1/en not_active Ceased
- 2014-10-20 CN CN201480071102.0A patent/CN105848654B/zh active Active
- 2014-10-20 AU AU2014340398A patent/AU2014340398A1/en not_active Abandoned
- 2014-10-20 CA CA2927148A patent/CA2927148A1/en not_active Abandoned
- 2014-10-20 MX MX2016004678A patent/MX2016004678A/es unknown
- 2014-10-20 US US15/030,713 patent/US9511050B2/en active Active
-
2016
- 2016-04-21 IL IL245281A patent/IL245281A0/en unknown
- 2016-11-30 US US15/365,794 patent/US20170157089A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6389884B2 (ja) | 2018-09-12 |
| WO2015061229A1 (en) | 2015-04-30 |
| RU2016114498A3 (enExample) | 2018-08-13 |
| US9511050B2 (en) | 2016-12-06 |
| US20170157089A1 (en) | 2017-06-08 |
| CA2927148A1 (en) | 2015-04-30 |
| AU2014340398A1 (en) | 2016-06-09 |
| CN105848654A (zh) | 2016-08-10 |
| CN105848654B (zh) | 2018-10-02 |
| IL245281A0 (en) | 2016-06-30 |
| JP2016534084A (ja) | 2016-11-04 |
| EP3060207A4 (en) | 2017-04-12 |
| US20160263086A1 (en) | 2016-09-15 |
| KR20160065986A (ko) | 2016-06-09 |
| RU2016114498A (ru) | 2017-11-29 |
| EP3060207A1 (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| EA201591674A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| MX2020009223A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| MX2016002974A (es) | Eteres de arilo y sus usos. | |
| SG11201510751YA (en) | Composition and vaccine for treating prostate cancer | |
| MX371108B (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
| MX370573B (es) | Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer. | |
| PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| TW201611843A (en) | Methods of treatment with arginine deiminase | |
| PH12018502569A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| IN2014DN09228A (enExample) | ||
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| GEP20197049B (en) | Compositions and methods for treating surface wounds | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| IL241823B (en) | Preparations containing novyi .c and their uses for the treatment of cancerous tumors | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| EA032501B9 (ru) | Способы и композиции для содействия заживлению острой раны и хронической раны | |
| MX2015013021A (es) | 5-bromo-indirrubinas. | |
| MX2014012535A (es) | Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. | |
| MX369455B (es) | Métodos mejorados para tratamiento de grano con ozono. |